ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in the United States. The company is a pioneer in high performance cell analysis platforms for life science research, with a focus on pre-clinical drug discovery, toxicology, safety pharmacology, and basic academic research. ACEA's flagship products, the xCELLigence® Real-Time Cell Analysis instruments and NovoCyte® aQuanteon flow cytometers, have seen significant adoption, with over 2,500 instruments placed globally and featured in more than 1,800 peer-reviewed publications.
The company recently received a $20.00M Venture Round investment on 01 March 2019, with Qiming Venture Partners being the lead investor. This investment reflects a strong affirmation of ACEA's potential and the industry's confidence in its innovative cell analysis technology. As a part of Agilent Technologies, ACEA Biosciences is well-positioned to further strengthen its market presence and expand its offerings in the biotechnology sector.
With a solid track record and strategic partnerships, ACEA Biosciences continues to be at the forefront of driving advancements in cell analysis technology, making it an attractive investment opportunity for venture capitalists seeking exposure to the thriving biotechnology industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $20.00M | 1 |
|
01 Mar 2019 |
| Series E | $15.00M | 1 |
|
01 Mar 2018 |
| Series E | $6.00M | 2 |
|
01 Apr 2016 |
| Venture Round | $30.00M | 2 |
|
09 Nov 2015 |
No recent news or press coverage available for ACEA Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
